Tag Archives: post-approval strategies

Takeaways from the Post-Approval Summit

Dr. Richard Gliklich, president of Quintiles Outcome and a professor at Harvard Medical School, highlights the most prominent post-approval issues and risks coming out of this year’s Post-Approval Summit, held on May 7th-8th. Brand managers prodding products across the regulatory finish line to commercialization are finding themselves in yet another race, instead of in the […]
Posted in Technology | Also tagged , , , , , , , , , , , | Leave a comment

Post-Approval Regulatory Priorities: Progress or Pile-Up?

An enduring falsehood about the pharmaceutical industry is that the heavy lifting ends with a successful new drug registration. What comes after is the equivalent of a well-funded retirement, where providers embrace the therapy, payers meet the price, and patients push the boundaries of clinical practice toward lucrative new indications. The reality, however, is starkly […]
Posted in Regulatory | Also tagged , , , , | 2 Comments
  • Categories

  • Meta